Breaking News

MilliporeSigma Opens $65M CDMO Facility for Cancer Therapies

Expansion doubles production of the most highly potent active pharmaceutical ingredients (HPAPIs).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, has doubled its high-potent active pharmaceutical ingredients (HPAPI) production capacity with the expansion of its facility in Verona, near Madison, WI. This new $65 million, 70,000 square foot facility brings 50 new jobs to the area. “There is an increasing demand for HPAPIs due to their effectiveness against cancer at lower doses and the trend towards more targeted therapeutics. Lower-doses of these therapies reduce t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters